Scarica l'app Stockscreener
1.54
0.65%
-0.01
Dopo l'orario di chiusura:
1.53
-0.01
-0.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.55
Aprire:
$1.56
Volume 24 ore:
7,863
Relative Volume:
0.57
Capitalizzazione di mercato:
$17.99M
Reddito:
$996.00K
Utile/perdita netta:
$-6.09M
Rapporto P/E:
0.343
EPS:
4.49
Flusso di cassa netto:
$-9.76M
1 W Prestazione:
-1.91%
1M Prestazione:
-6.24%
6M Prestazione:
-18.09%
1 anno Prestazione:
-30.32%
Intervallo 1D:
$1.5201
$1.57
Intervallo di 1 settimana:
$1.52
$1.5854
Portata 52W:
$1.4302
$3.07
Therapeuticsmd Inc Stock (TXMD) Company Profile
Nome
Therapeuticsmd Inc
Settore
Telefono
561-961-1900
Indirizzo
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-08-07 | Downgrade | Jefferies | Hold → Underperform |
| 2020-05-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Iniziato | Guggenheim | Buy |
| 2019-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-30 | Ripresa | Noble Capital Markets | Outperform |
| 2018-06-15 | Iniziato | JP Morgan | Overweight |
| 2017-09-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Ripresa | Jefferies | Buy |
| 2016-11-22 | Iniziato | Oppenheimer | Outperform |
| 2016-11-07 | Ripresa | Guggenheim | Buy |
| 2016-04-04 | Iniziato | Goldman | Buy |
| 2015-12-08 | Reiterato | Jefferies | Buy |
| 2015-12-08 | Reiterato | Stifel | Buy |
| 2015-09-21 | Reiterato | Jefferies | Buy |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2014-07-08 | Iniziato | FBR Capital | Outperform |
| 2014-04-17 | Reiterato | Noble Financial | Buy |
| 2014-01-28 | Reiterato | Noble Financial | Buy |
Mostra tutto
Therapeuticsmd Inc Borsa (TXMD) Ultime notizie
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD Inc. stock remains steady Thursday, still outperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Tuesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Thursday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock remains steady Thursday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock remains steady Friday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Sexual Wellness Market to Witness 4.7% CAGR by 2031 | SkyQuest Technology - Benzinga
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD announces revised shareholder proposal deadline By Investing.com - Investing.com Australia
TherapeuticsMD announces revised shareholder proposal deadline - Investing.com India
Tourmaline Bio (NASDAQ:TRML) Shares Up 3.9% - Defense World
This company generates no revenue and its market cap is over $20 billion. Here's why that valuation - The Bharat Express News
Commonwealth Equity Services LLC Has $979,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX) - Defense World
WINTON GROUP Ltd Buys New Shares in Tactile Systems Technology, Inc. (NASDAQ:TCMD) - MarketBeat
TransMedics Stock: Take Profits While The Valuation Is Sky High (NASDAQ:TMDX) - Seeking Alpha
Somite’s SMT-M01 awarded US orphan drug designation for Duchenne muscular dystrophy - BioWorld Online
Transmedics Group Inc (TMDX) deserves deeper analysis - US Post News
This is why everyone is talking about Summit TherapeuticsTHE BHARAT EXPRESS NEWS - The Bharat Express News
Here's Why Everyone's Talking About Summit Therapeutics - The Motley Fool
An analyst sees good growth prospects for Transmedics Group Inc (TMDX) - SETE News
Implant maker Tenon Medical nearly triples its market capitalization in two days - Kursiv Media
TD Asset Management Inc Invests $2.08 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit lifts Instil, BioNTech on Merck beating data (NASDAQ:SMMT) - Seeking Alpha
Therapeuticsmd Inc Azioni (TXMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Therapeuticsmd Inc Azioni (TXMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
| Walker Marlan D | Chief Executive Officer |
Dec 05 '23 |
Option Exercise |
0.00 |
70,000 |
0 |
81,615 |
| Walker Marlan D | Chief Executive Officer |
Dec 06 '23 |
Sale |
2.31 |
14,500 |
33,496 |
67,115 |
| Walker Marlan D | Chief Executive Officer |
Dec 07 '23 |
Sale |
2.24 |
4,550 |
10,187 |
62,565 |
0.88%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):